Aliscon SLE reaches major endpoint in phase 3 clinical trial of single anti-drug anifrolumab

SLE is an autoimmune disease with a incidence rate of about 30 cases per 100,000 people in ChinaAbout 90% of SLE patients are femaleToday, AstraZeneca announced that its, http:// for the treatment of systemic lupus erythematosus (SLE
), had reached a major endpoint of significant improvement in the critical phase 3 clinicaltrial(http://TULIP 2on AnifrolumabAnifrolumab is a monoclonal antibody that inhibits the type I interferon signaling pathwayAnifrolumab can be combined with sub-base 1 of the type I interferon receptor to antagonise all type 1 interferons (IFN-alpha, IFN-beta, and IFN-toy) related activitiesType I interferon is a class of cytokines involved in an inflammatory responseIFN-alpha promotes the activation and differentiation of various immune cells, including promoting the differentiation of autoactive B lymphocytes into plasma cells that secrete immunoglobulins, promoting dendritic cells maturation and inducing their expression of B-cell activation factors (BAFF) and proliferation-induced ligands (APRIL)Between 60% and 80% of SLE patients had high expression characteristics of type I interferon, and the concentration of type I interferon was positively correlated with the SLE patient disease activity index (SLEDAI) scoreIn the study
373 patients with moderate to severe SLE were randomly divided into two groups and received 300 mg of anifrolumab, or placebo, every 4 weeks, on the basis of standard therapyThe results showed that anifrolumab significantly improved the BILAG-based Lupus Comprehensive Evaluation Index (BICLA), which provided statistically significant and clinically significant remission to the patient's conditionThe improvement of BICLA means that disease activity in all organs of the patient has improved and there are no new outbreaks of disease